HFCAS OpenIR

Browse/Search Results:  1-10 of 31 Help

Selected(0)Clear Items/Page:    Sort:
Repurposing of Kinase Inhibitors for Treatment of COVID-19 期刊论文
PHARMACEUTICAL RESEARCH, 2020, 卷号: 37
Authors:  Weisberg, Ellen;  Parent, Alexander;  Yang, Priscilla L.;  Sattler, Martin;  Liu, Qingsong;  Liu, Qingwang;  Wang, Jinhua;  Meng, Chengcheng;  Buhrlage, Sara J.;  Gray, Nathanael;  Griffin, James D.
Favorite  |  View/Download:0/0  |  Submit date:2020/10/26
Coronavirus  SARS-CoV-2  SARS-CoV  MERS-CoV  kinase inhibitors  pharmacokinetics  antiviral therapy  COVID-19  
Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML) 期刊论文
CANCER BIOLOGY & THERAPY, 2019, 卷号: 20, 期号: 6, 页码: 877-885
Authors:  Wu, Jiaxin;  Wang, Aoli;  Li, Xixiang;  Chen, Cheng;  Qi, Ziping;  Hu, Chen;  Wang, Wenliang;  Wu, Hong;  Huang, Tao;  Zhao, Ming;  Wang, Wenchao;  Hu, Zhenquan;  Liu, Qingwang;  Wang, Beilei;  Wang, Li;  Li, Lili;  Ge, Jian;  Ren, Tao;  Xia, Ruixiang;  Liu, Jing
Favorite  |  View/Download:11/0  |  Submit date:2019/11/27
BCR-ABL  PDGFR  chronic myeloid leukemia  kinase inhibitor  
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia 期刊论文
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 卷号: 160, 页码: 61-81
Authors:  Liu, Xuesong;  Wang, Beilei;  Chen, Cheng;  Jiang, Zongru;  Hu, Chen;  Wu, Hong;  Zhang, Yicong;  Liu, Xiaochuan;  Wang, Wenliang;  Wang, Junjie;  Hu, Zhenquan;  Wang, Aoli;  Huang, Tao;  Liu, Qingwang;  Wang, Wei;  Wang, Li;  Wang, Wenchao;  Ren, Tao;  Li, Lili;  Xia, Ruixiang;  Ge, Jian;  Liu, Qingsong;  Liu, Jing
Adobe PDF(4593Kb)  |  Favorite  |  View/Download:126/89  |  Submit date:2019/01/11
ABL kinase  Kinase inhibitor  ABL mutant  CML  
Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrinnido[5,4-b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors 期刊论文
JOURNAL OF MEDICINAL CHEMISTRY, 2018, 卷号: 61, 期号: 10, 页码: 4608-4627
Authors:  Xue, Yu;  Song, Peiran;  Song, Zilan;  Wang, Aoli;  Tong, Linjiang;  Geng, Meiyu;  Ding, Jian;  Liu, Qingsong;  Sun, Liping;  Xie, Hua;  Zhang, Ao
View  |  Adobe PDF(6587Kb)  |  Favorite  |  View/Download:99/93  |  Submit date:2019/08/23
Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFR alpha kinase inhibitor for PDGFR alpha driving chronic eosinophilic leukemia 期刊论文
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 卷号: 150, 期号: 无, 页码: 366-384
Authors:  Wang, Qiang;  Liu, Feiyang;  Qi, Shuang;  Qi, Ziping;  Yan, Xiao-E.;  Wang, Beilei;  Wang, Aoli;  Wang, Wei;  Chen, Cheng;  Liu, Xiaochuan;  Jiang, Zongru;  Hu, Zhenquan;  Wang, Li;  Wang, Wenchao;  Ren, Tao;  Zhang, Shanchun;  Yun, Cai-Hong;  Liu, Qingsong;  Liu, Jing
View  |  Adobe PDF(5108Kb)  |  Favorite  |  View/Download:497/485  |  Submit date:2019/06/10
PDGFR kinase  Type II inhibitor  Kinase inhibitor  CEL  
Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibi 期刊论文
Eur. J. Med. Chem., 2018
Authors:  Qiang Wang;  Feiyang Liu;  Qi S(亓爽);  Ziping Qi;  Beilei Wang;  Aoli Wang;  Zongru Jiang;  Wenchao Wang;  Qingsong Liu;  Jing Liu
View  |  Adobe PDF(5108Kb)  |  Favorite  |  View/Download:18/0  |  Submit date:2020/10/20
Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report 期刊论文
FRONTIERS OF MEDICINE, 2018, 卷号: 12
-
Favorite  |  View/Download:0/0  |  Submit date:2020/10/26
BCL-2 INHIBITOR  MIDOSTAURIN  CLASSIFICATION  DECITABINE  MECHANISMS  MUTATIONS  TARGETS  IDH  BTK  venetoclax  cytarabine  AML  leukemia  
Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML 期刊论文
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 20, 页码: 8407-8424
Authors:  Wang, Aoli;  Li, Xixiang;  Chen, Cheng;  Wu, Hong;  Qi, Ziping;  Hu, Chen;  Yu, Kailin;  Wu, Jiaxin;  Liu, Juan;  Liu, Xiaochuan;  Hu, Zhenquan;  Wang, Wei;  Wang, Wenliang;  Wang, Wenchao;  Wang, Li;  Wang, Beilei;  Liu, Qingwang;  Li, Lili;  Ge, Jian;  Ren, Tao;  Zhang, Shanchun;  Xia, Ruixiang;  Liu, Jing;  Liu, Qingsong
View  |  Adobe PDF(10028Kb)  |  Favorite  |  View/Download:14/7  |  Submit date:2019/06/17
c-Abl inhibition mitigates diet-induced obesity through improving insulin sensitivity of subcutaneous fat in mice 期刊论文
DIABETOLOGIA, 2017, 卷号: 60, 期号: 5, 页码: 900-910
Authors:  Wu, Rong;  Sun, Jian-guang;  Wang, Ji-qiu;  Li, Binhua;  Liu, Qingsong;  Ning, Guang;  Jin, Wanzhu;  Yuan, Zengqiang
Favorite  |  View/Download:8/0  |  Submit date:2018/07/26
针对FLT3-ITD阳性急性髓细胞白血病的激酶抑制剂药物学研究 学位论文
, 合肥: 中国科学技术大学, 2017
Authors:  王傲莉
Adobe PDF(7111Kb)  |  Favorite  |  View/Download:55/0  |  Submit date:2018/01/18